Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP.

Inflammation is a significant factor in cancer development, and a molecular understanding of the parameters dictating the impact of inflammation on cancers could significantly improve treatment. The tumor suppressor p53 is frequently mutated in cancer, and p53 missense mutants (mutp53) can acquire oncogenic properties. We report that cancer cells with mutp53 respond to inflammatory cytokines increasing their invasive behavior. Notably, this action is coupled to expression of chemokines that can expose the tumor to host immunity, potentially affecting response to therapy. Mechanistically, mutp53 fuels NF-κB activation while it dampens activation of ASK1/JNK by TNFα, and this action depends on mutp53 binding and inhibiting the tumor suppressor DAB2IP in the cytoplasm. Interfering with such interaction reduced aggressiveness of cancer cells in xenografts. This interaction is an unexplored mechanism by which mutant p53 can influence tumor evolution, with implications for our understanding of the complex role of inflammation in cancer.

[1]  R. Gascoyne,et al.  Lymphotoxin network pathways shape the tumor microenvironment. , 2013, Current opinion in immunology.

[2]  R. Langer,et al.  Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. , 2013, Cancer cell.

[3]  D Saur,et al.  Cross talk between stimulated NF-κB and the tumor suppressor p53 , 2010, Oncogene.

[4]  Shalom Madar,et al.  Mutant p53 gain of function is interwoven into the hallmarks of cancer , 2011, The Journal of pathology.

[5]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[6]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[7]  Huqun,et al.  Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells , 2005, European journal of immunology.

[8]  Jeong-Seok Nam,et al.  TNFα-exposed Bone Marrow-derived Mesenchymal Stem Cells Promote Locomotion of MDA-MB-231 Breast Cancer Cells through Transcriptional Activation of CXCR3 Ligand Chemokines* , 2010, The Journal of Biological Chemistry.

[9]  Wareef Kabbani,et al.  Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis , 2010, Proceedings of the National Academy of Sciences.

[10]  M. Salto‐Tellez,et al.  Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. , 2007, Journal of hepatology.

[11]  Vassilis G Gorgoulis,et al.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. , 2013, Cancer cell.

[12]  土手 秀昭.  Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer , 2004 .

[13]  Wang Min,et al.  AIP1/DAB2IP, a Novel Member of the Ras-GAP Family, Transduces TRAF2-induced ASK1-JNK Activation* , 2004, Journal of Biological Chemistry.

[14]  R. Vessella,et al.  DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis , 2009, Proceedings of the National Academy of Sciences.

[15]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[16]  D. Menendez,et al.  Modulation of immune responses by the tumor suppressor p53 , 2013 .

[17]  Shalom Madar,et al.  Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature , 2012, Journal of Cell Science.

[18]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[19]  V. Rotter,et al.  Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. , 2007, Cancer research.

[20]  Paolo Provero,et al.  A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network , 2010, Proceedings of the National Academy of Sciences.

[21]  Antonio Rosato,et al.  A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis , 2009, Cell.

[22]  W. Min,et al.  AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. , 2003, The Journal of clinical investigation.

[23]  W. Min,et al.  AIP 1 Recruits Phosphatase PP 2 A to ASK 1 in Tumor Necrosis Factor – Induced ASK 1-JNK Activation , 2008 .

[24]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[25]  S. Deb,et al.  Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. , 2012, Carcinogenesis.

[26]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[27]  D. Walerych,et al.  The rebel angel: mutant p53 as the driving oncogene in breast cancer , 2012, Carcinogenesis.

[28]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[29]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[30]  S. Bicciato,et al.  Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast , 2013, EMBO molecular medicine.

[31]  M. Duffy,et al.  Metalloproteinases: role in breast carcinogenesis, invasion and metastasis , 2000, Breast Cancer Research.

[32]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[33]  Y. Hsieh,et al.  Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. , 2010, European journal of cell biology.

[34]  H. Zeh,et al.  NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. , 2012, Cancer research.

[35]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[36]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[37]  Darjus F. Tschaharganeh,et al.  Non-Cell-Autonomous Tumor Suppression by p53 , 2013, Cell.

[38]  W. Willett,et al.  Breast cancer (1) , 1992, The New England journal of medicine.

[39]  Jérôme Galon,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[40]  You-ji Feng,et al.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway , 2009, Molecular Cancer.

[41]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[42]  V. Baron,et al.  Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells , 2010, Oncogene.

[43]  S. Ahn,et al.  Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients , 2013, Journal of breast cancer.

[44]  Yu Shyr,et al.  A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance , 2011, Clinical Cancer Research.

[45]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[46]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[47]  C. Heldin,et al.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.